AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results

We recently published 12 Best Healthcare Stocks to Buy Under $30. AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare stocks.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including cancer, metabolic, endocrine, and autoimmune disorders. Their integrated platform combines technology, data science, and collaboration to identify promising antibody candidates.

In recent developments, AbCellera Biologics Inc. (NASDAQ:ABCL) began dosing participants in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms related to menopause, marking a key clinical milestone. The company reported strong Q2 2025 revenue growth, beating expectations and advancing both internal and partnered antibody programs despite ongoing net losses. Some analysts note that its innovative pipeline and expanding clinical presence could place it among the best healthcare stocks to watch in the biotech space.

This Phase 1 trial signals the corporation’s shift from primarily a discovery platform to a clinical-stage biotech with proprietary assets. Progress with ABCL635 addresses a significant unmet medical need and validates its platform’s potential to develop first-in-class therapeutics.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.